simendan has been researched along with Cardiomyopathies, Primary in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 13 (52.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budde, H; Cimiotti, D; Fujita-Becker, S; Gärtner, A; Hamdani, N; Hassoun, R; Herrmann, C; Jaquet, K; Klingel, K; Krause, V; Laser, KT; Lódi, M; Majchrzak, M; Mannherz, HG; Milting, H; Möhner, D; Mügge, A; Nowaczyk, MM; Pfitzer, G; Schaaf, T; Schröder, RR; Stehle, R; Sultana, I | 1 |
| Chen, N; Cui, N; Ding, XX; Li, N; Sun, T; Wang, SH; Yu, ZB; Zhang, N | 1 |
| Couture, EJ; Nabzdyk, C; Radosevich, M | 1 |
| Guan, Q; Huang, D; Li, A; Li, B; Qin, J; Zhang, C; Zhang, X | 1 |
| Faggian, G; Onorati, F; Veraldi, G | 1 |
| Bergounioux, J; Essid, A; Haegy, I; Josseran, L; Mbieleu, B; Sumanaru, D | 1 |
| Chen, Z; Sun, Y; Yang, F; Zhao, LN | 1 |
| Franz, WM; Grabmaier, U; Hagl, C; Kaczmarek, I; Kreissl, N; Sodian, R; Steinbeck, G; Theiss, HD | 1 |
| Beutlhauser, T; Erb, J; Feldheiser, A; Grubitzsch, H; Schuster, B; Spies, C; Treskatsch, S | 1 |
| Bleilevens, C; Hein, M; Roehl, AB; Rossaint, R; Tolba, R; Zoremba, N | 1 |
| Avram, R; Desplantie, O; Ducharme, A; Jolicoeur, EM; Marquis-Gravel, G; Tremblay-Gravel, M | 1 |
| Friedrich, O; Hein, S; Schürmann, S; Schüttler, J; Wagner, S | 1 |
| Akhtar, MS; Dhyani, N; Hassan, MQ; Ismail, MV; Najmi, AK; Pillai, KK | 1 |
| Arrigo, M; Brandão, JL; Feliot, E; Ferjani, M; Gayat, E; Hajjej, Z; Labbene, I; Mebazaa, A; Tavares, M; Tolppanen, H | 1 |
| Apostolakis, S; Lazaridis, K; Spandidos, DA; Tzoras, S; Zaravinos, A | 1 |
| Akgün, T; Biteker, M; Duran, NE; Gökdeniz, T; Gündüz, S; Kahveci, G; Kaya, H; Õzkan, M; Tanboğa, HÎ; Yildiz, M | 1 |
| Kantor, PF; Timberlake, K | 1 |
| Kilo, J; Schermer, E; Schweigmann, U; Velik-Salchner, C | 1 |
| Behrends, M; Peters, J | 1 |
| Benlolo, S; Katchatouryan, V; Lefoll, C; Mebazaa, A; Payen, D | 1 |
| Krouzecky, A; Matejovic, M; Novak, I; Radej, J | 1 |
| Huang, L; Sun, S; Tang, W; Wang, J; Weil, MH | 1 |
| Ayoub, IM; Gazmuri, RJ; Kolarova, JD | 1 |
| Beiras-Fernandez, A; Fuchs, H; Meiser, BM; Reichart, B; Weis, FC; Weis, M | 1 |
| Adamopoulos, S; Farmakis, D; Filippatos, G; Iliodromitis, E; Kremastinos, DT; Panou, F; Paraskevaidis, I; Parissis, JT | 1 |
3 review(s) available for simendan and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Meta-Analysis of the Efficacy of Levosimendan in the Treatment of Severe Sepsis Complicated with Septic Cardiomyopathy.
Topics: Adult; Calcium; Cardiomyopathies; Cardiotonic Agents; Humans; Hydrazones; Multiple Organ Failure; Pyridazines; Sepsis; Simendan; Stroke Volume; Ventricular Function, Left | 2023 |
Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application.
Topics: Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Humans; Prognosis; Sepsis; Simendan | 2019 |
The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies.
Topics: Bromocriptine; Cardiomyopathies; Echocardiography; Female; Humans; Hydrazones; Pentoxifylline; Pregnancy; Pregnancy Complications, Cardiovascular; Prospective Studies; Puerperal Disorders; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Ventricular Dysfunction, Left | 2015 |
5 trial(s) available for simendan and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Efficacy of Levosimendan in the Treatment of Patients With Severe Septic Cardiomyopathy.
Topics: Cardiomyopathies; Cardiotonic Agents; Dobutamine; Humans; Hydrazones; Norepinephrine; Prospective Studies; Pyridazines; Sepsis; Shock, Septic; Simendan; Single-Blind Method; Stroke Volume; Ventricular Function, Left | 2023 |
Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiomyopathies; Cardiotonic Agents; Coronary Artery Bypass; Double-Blind Method; Enoximone; Female; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Norepinephrine; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2014 |
Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Biomarkers; Cardiomyopathies; DNA; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2011 |
Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial.
Topics: Adult; Cardiomyopathies; Cardiovascular Agents; Drug Therapy, Combination; Echocardiography; Female; Heart Ventricles; Humans; Hydrazones; Peripartum Period; Predictive Value of Tests; Pregnancy; Pregnancy Complications, Cardiovascular; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left; Young Adult | 2011 |
Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Cytokines; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Immunity, Cellular; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan; Treatment Outcome; Troponin T; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
17 other study(ies) available for simendan and Cardiomyopathies, Primary
| Article | Year |
|---|---|
De Novo Missense Mutations in
Topics: Adenosine Triphosphatases; Adult; Calcium; Cardiomyopathies; Catechin; Humans; Infant; Male; Microscopy, Electron, Transmission; Mutation, Missense; Myofibrils; Sarcomeres; Severity of Illness Index; Simendan; Tropomyosin; Troponin I | 2021 |
Levosimendan And Septic Cardiomyopathy: A Key That May Have Found Its Lock?
Topics: Cardiomyopathies; Cardiotonic Agents; Humans; Hydrazones; Shock, Septic; Simendan | 2023 |
Commentary: The quest for the holy grail continues: Is levosimendan the best choice to support patients with cardiomyopathy requiring cardiac surgery?
Topics: Cardiac Surgical Procedures; Cardiomyopathies; Heart; Humans; Simendan; Ventricular Function, Left | 2020 |
Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.
Topics: Acute Disease; Adult; Cardiomyopathies; Cardiotonic Agents; Heart Failure; Humans; Lactic Acid; Male; Muscular Dystrophy, Duchenne; Natriuretic Peptide, Brain; Pneumonia; Simendan | 2019 |
Preconditioning with levosimendan before implantation of left ventricular assist devices.
Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Female; Heart Failure; Heart-Assist Devices; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome | 2014 |
Insular infarct size but not levosimendan influenced myocardial injury triggered by cerebral ischemia in rats.
Topics: Animals; Blood Pressure; Brain; Brain Ischemia; Cardiomyopathies; Hemodynamics; Hydrazones; Male; Neuroprotective Agents; Pyridazines; Rats; Rats, Wistar; Simendan | 2015 |
Septic cardiomyopathy in rat LPS-induced endotoxemia: relative contribution of cellular diastolic Ca(2+) removal pathways, myofibrillar biomechanics properties and action of the cardiotonic drug levosimendan.
Topics: Animals; Calcium; Cardiomyopathies; Cardiotonic Agents; Endotoxemia; Hemodynamics; Homeostasis; Hydrazones; Lipopolysaccharides; Male; Microscopy, Confocal; Myofibrils; Pyridazines; Rats; Rats, Wistar; Sarcolemma; Simendan | 2015 |
Levosimendan reduces myocardial damage and improves cardiodynamics in streptozotocin induced diabetic cardiomyopathy via SERCA2a/NCX1 pathway.
Topics: Animals; Body Weight; Cardiomyopathies; Cardiotonic Agents; Diabetes Mellitus, Experimental; Heart; Hemodynamics; Hydrazones; Male; Natriuretic Peptide, Brain; Nitric Oxide; Pyridazines; Rats; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Calcium Exchanger; Streptozocin; Transforming Growth Factor beta; Troponin I | 2016 |
Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy.
Topics: Adult; Aged; Atrial Function, Right; Blood Pressure; Cardiac Output; Cardiomyopathies; Cardiotonic Agents; Catheterization; Echocardiography; Female; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Postpartum Period; Pulmonary Artery; Pyridazines; Retrospective Studies; Shock, Cardiogenic; Simendan; Stroke Volume | 2017 |
Pharmacologic therapy of heart failure in children: part of a special series on paediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Cardiotonic Agents; Child; Digoxin; Diuretics; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
How mechanical circulatory support helps not to need it--new strategies in pediatric heart failure.
Topics: Adolescent; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Child, Preschool; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant; Male; Milrinone; Myocarditis; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Guinea Pigs; Hydrazones; In Vitro Techniques; Lipopolysaccharides; Male; Prospective Studies; Pyridazines; Random Allocation; Simendan; Ventricular Function, Left | 2003 |
Successful use of levosimendan in a patient with peripartum cardiomyopathy.
Topics: Adult; Anesthesia, Obstetrical; Apnea; Cardiomyopathies; Female; Hemodynamics; Humans; Hydrazones; Pregnancy; Pregnancy Complications, Cardiovascular; Pyridazines; Simendan; Vasodilator Agents | 2004 |
Successful reversal of resistent hypodynamic septic shock with levosimendan.
Topics: Adult; Cardiac Output; Cardiomyopathies; Cardiotonic Agents; Female; Humans; Hydrazones; Immunocompromised Host; Pyridazines; Shock, Septic; Simendan | 2005 |
Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction.
Topics: Analysis of Variance; Animals; Cardiomyopathies; Cardiopulmonary Resuscitation; Cardiotonic Agents; Dobutamine; Heart Arrest; Hydrazones; Male; Myocardial Stunning; Prospective Studies; Pyridazines; Random Allocation; Simendan; Swine | 2005 |
Inotropic options for postresuscitation myocardial dysfunction.
Topics: Animals; Cardiomyopathies; Cardiopulmonary Resuscitation; Cardiotonic Agents; Dobutamine; Heart Arrest; Humans; Hydrazones; Myocardial Stunning; Pyridazines; Simendan; Swine | 2005 |
Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery?
Topics: Adolescent; Aged; Calcium; Cardiomyopathies; Catecholamines; Female; Heart; Heart Transplantation; Humans; Hydrazones; Ischemia; Male; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 2006 |